Synergistic anticancer effects of Pam3CSK4 and Ara-C on B-cell lymphoma cells
Sae-Kyung Lee1, Jyh Y Chwee2, Cheryl A P Ma1
1Authors' Affiliations: Immunology Programme, Centre for Life Sciences, Department of Microbiology; and.
Purpose:
The low immunogenicity of many cancer cells and the immunosuppression by various cancers and anticancer therapies have been an obstacle in the development of efficacious immunotherapies. Our goal was to test whether Toll-like receptor (TLR) agonists and anticancer chemotherapeutic agents synergize in rendering tumor cells more immunogenic.
Experimental Design:
We treated B-cell lymphoma cells with the TLR1/2 agonist Pam3CSK4 and the genotoxic anticancer agent 1-β-D-arabinofuranosylcytosine (Ara-C). The effects on the immunogenicity of tumor cells were measured in transfer experiments and in vitro studies.
Results:
The treatment of B-cell lymphoma cells with the TLR1/2 agonist Pam3CSK4 enhanced the anticancer effects of the genotoxic agent Ara-C. Mice injected with cotreated tumor cells survived longer than mice challenged with Pam3CSK4 or Ara-C-treated cells. Administration of Pam3CSK4 or Ara-C reduced the tumor load of mice injected with tumor cells. Cotreatment had no effect on the rate of apoptosis or proliferation of Ara-C-treated cells, but upregulated the expression of several immunomodulatory molecules. Consistent with an increased immunogenicity of Pam3CSK4 and Ara-C-treated B-cell lymphoma cells, rejection of cotreated tumor cells required natural killer cells and T cells. We demonstrate that the upregulation of immunomodulatory molecules in response to Pam3CSK4 and Ara-C depended in part on NF-κB.
Conclusion:
TLR agonists can increase the efficacy of conventional cancer therapies by altering the immunogenicity of B-cell lymphoma cells.
Insights
Toll-like receptor (TLR) agonists combined with chemotherapy enhance cancer cell immunogenicity. This combination therapy improves survival and reduces tumor load by upregulating immune-modulating molecules, offering a promising approach for cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Cancer cells often exhibit low immunogenicity, hindering effective immunotherapy.
- Tumor-induced immunosuppression and therapies can further impede anti-cancer immune responses.
Purpose of the Study:
- To investigate the synergistic effects of Toll-like receptor (TLR) agonists and chemotherapeutic agents on tumor cell immunogenicity.
- To determine if combining TLR agonists with chemotherapy can enhance anti-cancer immunity.
Main Methods:
- B-cell lymphoma cells were treated with a TLR1/2 agonist (Pam3CSK4) and a chemotherapeutic agent (Ara-C).
- Immunogenicity was assessed through in vivo tumor rejection assays and in vitro studies measuring molecular expression.
- The role of NF-κB in mediating the observed effects was investigated.
Main Results:
- Combination treatment of B-cell lymphoma cells with Pam3CSK4 and Ara-C enhanced anti-cancer efficacy and prolonged survival in mice.
- Cotreatment reduced tumor load and upregulated key immunomodulatory molecules without affecting apoptosis or proliferation.
- Tumor cell rejection in cotreated groups required the action of natural killer cells and T cells, indicating enhanced immunogenicity.
Conclusions:
- TLR agonists can synergize with conventional chemotherapy to increase tumor cell immunogenicity.
- This approach holds potential for improving the efficacy of cancer therapies by boosting anti-tumor immune responses.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:31The Intrinsic Apoptotic Pathway
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:27Tumor Immunotherapy